Biotechnological war against biofilms. Could phages mean the end of device-related infections?

International Journal of Artificial Organs

Volumn 30, Issue 9, 2007, Pages 805-812

  Del Pozo, J L ^a   Alonso, M ^a   Arciola, C R ^b   Gonzalez, R ^a   Leiva, J ^a   Lasa, I ^c   Penades, J ^d  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

^d INSTITUTO VALENCIANO DE INVESTIGACIONES AGRARIAS IVIA   (Spain)

Author keywords

Biofilm; Phages; Staphylococcus aureus

Indexed keywords

ANTIBIOTICS; BACTERIA; BACTERIOPHAGES; DISEASES; IMPLANTS (SURGICAL);

ANTIBIOTIC ACTIVITY; BIOFILM FORMATION; CLINICAL FAILURE; CLINICAL PRACTICES; CLINICAL SETTINGS; IMPLANTABLE DEVICES; PLANKTONIC BACTERIA; SESSILE BACTERIA; THERAPEUTIC AGENTS; THERAPEUTIC USE;

BIOFILMS;

ANTIBIOTIC AGENT; VANCOMYCIN; VIROTHERAPY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIOLYSIS; BACTERIOPHAGE; BIOFILM; BIOTECHNOLOGY; CATHETER INFECTION; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; DRUG SPECIFICITY; NONHUMAN; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 36048965115     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880703000910     Document Type: Article

References (59)

1. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
2. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350: 1422-9.
3. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001; 358: 135-8.
4. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9: 34-9.
5. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
6. del Pozo JL, Serrera A, Martínez A, Leiva J, Penadés J, Lasa I. Biofilm related infections: Is there a place for conservative treatment of port-related bloodstream infections. Int J Artif Organs 2006; 29: 379-86.
7. Huebner J, Goldmann DA. Coagulase-negative staphylococci: role as pathogens. Annu Rev Med 1999; 50: 223-36.
8. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs 2005; 28: 1062-8. Review
9. Mack D, Rohde H, Harris LG, Davies AP, Horstkotte MA, Knobloch JK. Biofilm formation in medical device-related infection. Int J Artif Organs 2006; 29: 343-59.
10. von Eiff C, Arciola CR, Montanaro L, Becker K, Campoccia D. Emerging Staphylococcus species as new pathogens in implant infections. Int J Artif Organs 2006; 29: 360-7. Review.
11. Arciola CR, Campoccia D, An YH, Baldassarri L, Pirini V, Donati ME, Pegreffi F, Montanaro Prevalence and antibiotic resistance of 15 minor staphylococcal species colonizing orthopedic implants. Int J Artif Organs 2006; 29: 395-401.
12. Arciola CR, Alvi FI, An YH, Campoccia D, Montanaro L. Implant infection and infection resistant materials: a mini review. Int J Artif Organs 2005; 28: 1119-25. Review.
13. Reid G. Biofilms in infectious disease and on medical devices. Int J Antimicrob Agents 1999; 11: 223-6.
14. Richard P, Le Floch R, Chamoux C, Pannier M, Espaze E, Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J Infect Dis 1994; 170: 377-83.
15. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
16. Sulakvelidze A, Alavidze Z, Morris JG, Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649-59.
17. Ogunseitan OA, Sayler GS, Miller RV. Application of DNA probes to analysis of bacteriophage distribution patterns in the environment. Appl Environ Microbiol 1992; 58: 2046-52.
18. Skurnik M, Strauch E. Phage therapy: facts and fiction. Int J Med Microbiol 2006; 296: 5-14.
19. Thiel K. Old dogma, new tricks - 21st Century phage therapy. Nat Biotechnol 2004; 22: 31-6.
20. Sulakvelidze A, Morris JG, Jr. Bacteriophages as therapeutic agents. Ann Med 2001; 33: 507-9.
21. Ahrnad SI. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypotheses 2002; 58: 327-31.
22. Dixon B. New dawn for phage therapy. Lancet Infect Dis 2004; 4: 186.
23. Sulakvelidze A. Phage therapy: an attractive option for dealing with antibiotic-resistant bacterial infections. Drug Discov Today 2005; 10: 807-9.
24. Chernomordik AB. [Bacteriophages and their therapeuticprophylactic use]. Med Sestra 1989; 48: 44-7.
25. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307-18.
26. Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004; 48: 3817-22.
27. Cislo M, Dabrowski M, Weber-Dabrowska B, Woyton A. Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 1987; 35: 175-83.
28. Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 1987; 35: 569-83.
29. D'Herelle E The Bacteriophage and its behavior. Baltimore Williams and Wilkins 1926.
30. Bogovazova GG, Voroshilova NN, Bondarenko VM. [The efficacy of Klebsiella pneumoniae bacteriophage in the therapy of experimental Klebsiella infection]. Zh Mikrobiol Epidemiol Immunobiol 1991; 4: 5-8.
31. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 1992; 37: 258-61.
32. Tanji Y, Shimada T, Fukudomi H, Miyanaga K, Nakai Y, Unno H. Therapeutic use of phage cocktail for controlling Escherichia coli O157:H7 in gastrointestinal tract of mice. J Biosci Bioeng 2005; 100: 280-7.
33. Wang J, Hu B, Xu M, Yan Q, Liu S, Zhu X, et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 2006; 17: 309-17.
34. Wood HL, Holden SR, Bayston R. Susceptibility of Staphylococcus epidermidis biofilm in CSF shunts to bacteriophage attack. Eur J Pediatr Surg 2001; 11 (Suppl 1): S56-7.
35. Mathur MD, Vidhani S, Mehndiratta PL. Bacteriophage therapy: an alternative to conventional antibiotics. J Assoc Physicians India 2003; 51: 593-6.
36. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J infect Chemother 2005; 11: 211-9.
37. Sillankorva S, Oliveira R, Vieira MJ, Sutherland IW, Azeredo J. Bacteriophage Phi S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 2004; 20: 133-8.
38. Webb JS, Lau M, Kjelleberg S. Bacteriophage and phenotypic variation in Pseudomonas aeruginosa biofilm development: J Bacteriol 2004; 186: 8066-73.
39. Suthereland IW, Hughes KA, Skillman LC, Tait K. The interaction of phage and biofilms. FEMS Microbiol Lett 2004; 232: 1-6.
40. Stanley NR, Lazazzera BA. Environmental signals and regulatory pathways that influence biofilm formation. Mol Microbiol 2004; 52: 917-24.
41. McLean RJ, Corbin BD, Balzer GJ, Aron GM. Phenotype characterization of genetically defined microorganisms and growth of bacteriophage in biofilms. Methods Enzymol 2001; 336: 163-74.
42. Weiner R, Langille S, Quintero E. Structure, function and immunochemistry of bacterial exopolysaccharides. J Ind Microbiol 1995; 15: 339-46.
43. Pelkonen S, Aalto J, Finne J. Differential activities of bacteriophage depolymerase on bacterial polysaccharide: binding is essential but degradation is inhibitory in phage infection of K1-defective Escherichia coli. J Bacteriol 1992; 174: 7757-61.
44. Bayer ME, Thurow H, Bayer MH. Penetration of the polysaccharide capsule of Escherichia coli (Bi161/42) by bacteriophage K29. Virology 1979; 94: 95-118.
45. Hughes KA, Sutherland IW, Jones MV. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology 1998; 144 (Pt 11): 3039-47.
46. Corbin BD, McLean RJ, Aron GM. Bacteriophage T4 multiplication in a glucose-limited Escherichia coli biofilm. Can J Microbiol 2001; 47: 680-4.
47. Curtin JJ, Donlan RM. Using bacteriophages to reduce formation of catheter-associated biofilms by Staphylococcus epidermidis. Antimicrob Agents Chemother 2006; 50: 1268-75.
48. Adams M. Bacteriophages. N York Interscience Publishers 1959.
49. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 2000; 40: 175-9.
50. Bogovazova GG, Voroshilova NN, Bondarenko VM, Gorbatkova GA, Afanas'eva EV, Kazakova TB, et al. [Immunobiological properties and therapeutic effectiveness of preparations from Klebsielta bacteriophages]. Zh Mikrobiol Epidemiol Immunobiol 1992; 30-3.
51. Payne RJ, Jansen VA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 2001; 208: 37-48.
52. Kasman LM, Kasman A, Westwater C, Dolan J, Schmidt MG, Norris JS. Overcoming the phage replication threshold: a mathematical model with implications for phage therapy. J Virol 2002; 76: 5557-64.
53. Inchley CJ. The actvity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol 1969; 5: 173-87.
54. Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 563-8.
55. Babalova EG, Katsitadze KT, Sakvarelidze LA, Imnaishvili N, Sharashidze T-G, Badashvili VA, et al. [Preventive value of dried dysentery bacteriophage]. Zh Mikrobiol Epidemiol Immunobiol 1968; 45: 143-5.
56. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 2005; 49: 2874-8.
57. Brüssow H, Canchaya C, Hardt WD. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion, Microbiol Mol Biol Rev 2004; 68: 560-602.
58. McGrath S, Fitzgerald GF, van Sinderen D. The impact of bacteriophage genomics. Curr Opin Biotechnol 2004; 15: 94-9.
59. Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 553-61.